ORIFARM GENERICS A/S: Financial statements 2013
CVR: 25674030
Source: annual report 2013, Danish Business Authority
01/01/2013 – 31/12/2013
ORIFARM GENERICS A/S (CVR 25674030) has filed annual accounts for 2013. In 2013, the company reported a gross profit of DKK 30,716,000 and a net result of DKK 1,324,000. Equity in the 2013 report amounted to DKK 6,882,000. The solvency ratio was 20.1%.
- Gross Profit
- DKK 30,716,000
- Profit/Loss
- DKK 1,324,000
- Equity
- DKK 6,882,000
- Total Assets
- DKK 34,275,000
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2013
ORIFARM GENERICS A/S has published its annual report for 2012.
As of March 4, 2013, Ulrik Ernst Rasmussen is registered as adm. dir. of ORIFARM GENERICS A/S.
As of March 4, 2013, Erik Sandberg has stepped down as adm. dir. of ORIFARM GENERICS A/S.
About ORIFARM GENERICS A/S
ORIFARM GENERICS A/S is a Danish company of the type Aktieselskab based in Odense S, founded in 2000. The company is registered under the industry Engroshandel med læge- og hospitalsartikler. The company was previously named COPYFARM A/S and A/S PSE 38 NR. 2228. The management consists of Thomas Brandhof. The board consists of Hans Carl Bøgh-Sørensen (chair), Birgitte Bøgh-Sørensen, Mads Fink Eriksen and Nicki Lund Kristensen. The company is owned by ORIFARM GENERICS HOLDING A/S. The company has 255 employees (2026). In 2025, the company reported revenue of DKK 2,463,585,000 and a net result of DKK 77,177,000 compared with DKK 59,860,000 the year before. Equity in the 2025 report amounted to DKK 496,304,000.